Display options
Cite
Doğan EA, Doğan U, Genç E, et al. Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses. Ther Clin Risk Manag. 2018;14:1369-1377doi: 10.2147/TCRM.S171793.
Doğan, E. A., Doğan, U., Genç, E., Erdoğan, �. �., & Genç, B. O. (2018). Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses. Therapeutics and clinical risk management, 141369-1377. https://doi.org/10.2147/TCRM.S171793
Doğan, Ebru Apaydın, et al. "Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses." Therapeutics and clinical risk management vol. 14 (2018): 1369-1377. doi: https://doi.org/10.2147/TCRM.S171793
Doğan EA, Doğan U, Genç E, Erdoğan Ç, Genç BO. Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses. Ther Clin Risk Manag. 2018 Aug 02;14:1369-1377. doi: 10.2147/TCRM.S171793. eCollection 2018. PMID: 30122936; PMCID: PMC6080872.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2018 Aug 02;14:1369-1377. doi: 10.2147/TCRM.S171793. eCollection 2018.

Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses.

Therapeutics and clinical risk management

Ebru Apaydın Doğan, Umuttan Doğan, Emine Genç, Çağla Erdoğan, Bülent Oğuz Genç

Affiliations

  1. Department of Neurology, School of Medicine, Akdeniz University, Antalya, Turkey, [email protected].
  2. Department of Cardiology, School of Medicine, Akdeniz University, Antalya, Turkey.
  3. Department of Neurology, School of Medicine, Necmettin Erbakan University, Konya, Turkey.

PMID: 30122936 PMCID: PMC6080872 DOI: 10.2147/TCRM.S171793

Abstract

BACKGROUND: Data regarding lacosamide treatment as an adjunctive therapy in patients representative of a focal-onset epilepsy population including those with and without intellectual/developmental disorders (IDDs) are limited.

PURPOSE: To evaluate the retention rates of lacosamide in focal-onset epilepsy patients with and without IDD.

PATIENTS AND METHODS: We retrospectively reviewed all consecutive electronic and paper medical records of patients diagnosed with focal-onset epilepsy who were treated with lacosamide in two tertiary epilepsy centers.

RESULTS: One hundred and thirty-six patients who met the inclusion criteria were studied. Number of patients with IDD was 46 (33.8%). Median lacosamide dose was 300 mg/day. A total of 39 patients (28.7%) experienced side effects, and 22 of them (16.2%) discontinued lacosamide. The 1-, 2-, and 3-year retention rates of lacosamide in patients with IDD were 68%, 62%, and 53%, respectively. Kaplan-Meier survival analysis showed that the retention rates were significantly lower in patients with IDD when compared to patients without IDD (

CONCLUSION: When compared to patients without IDD, retention rates of lacosamide adjunctive therapy were lower in patients with IDD. However, these rates were higher than the rates suggested with previously registered AEDs including lamotrigine, levetiracetam, and topiramate. Therefore, irrespective of having comorbid IDD, we might suggest that lacosamide is a well-retained drug with a high efficacy profile in patients with focal-onset epilepsy.

Keywords: focal-onset epilepsy; intellectual/developmental disorders; lacosamide

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Epilepsia. 1998 Jul;39(7):799-803 - PubMed
  2. Epilepsy Behav. 2011 Jan;20(1):20-3 - PubMed
  3. Epilepsia. 2016 Sep;57(9):1416-25 - PubMed
  4. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(4):483-504 - PubMed
  5. J Intellect Disabil Res. 2005 Apr;49(Pt 4):296-305 - PubMed
  6. Clin Pharmacokinet. 2015 Sep;54(9):901-14 - PubMed
  7. CNS Drugs. 2017 Jul;31(7):527-534 - PubMed
  8. Seizure. 2017 Nov;52:123-130 - PubMed
  9. CNS Drugs. 2010 Dec;24(12):1055-68 - PubMed
  10. Epilepsia. 2017 Oct;58(10):1749-1754 - PubMed
  11. Clin Drug Investig. 2015 Feb;35(2):121-31 - PubMed
  12. J Neurol Neurosurg Psychiatry. 2003 Nov;74(11):1485-92 - PubMed
  13. Ther Clin Risk Manag. 2009;5:757-66 - PubMed
  14. Acta Neurol Scand. 2013 Mar;127(3):149-53 - PubMed
  15. Epilepsy Behav. 2018 Mar;80:25-32 - PubMed
  16. Seizure. 2013 Sep;22(7):528-36 - PubMed
  17. Epilepsy Behav. 2017 Mar;68:141-145 - PubMed
  18. Schweiz Med Wochenschr. 1963 Jan 12;93:107-10 - PubMed
  19. Epilepsy Behav. 2007 May;10(3):349-53 - PubMed
  20. Clin Neuropharmacol. 2015 Sep-Oct;38(5):198-200 - PubMed
  21. Seizure. 2006 Sep;15(6):376-86 - PubMed
  22. Epilepsy Behav. 2002 Aug;3(4):303-308 - PubMed
  23. Epilepsy Behav. 2007 Aug;11(1):92-7 - PubMed
  24. Adv Neurol. 1991;55:127-42 - PubMed
  25. Epilepsy Behav. 2017 Jun;71(Pt A):73-78 - PubMed
  26. Epilepsy Behav. 2010 May;18(1-2):24-30 - PubMed
  27. Seizure. 2016 Oct;41:96-9 - PubMed

Publication Types